Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Maren Dirnberger-Hertweck"'
Autor:
Johannes Duell, Kami J. Maddocks, Eva González-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven de Vos, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Nagesh Kalakonda, Marc André, Martin Dreyling, Tobias Menne, Olivier Tournilhac, Marinela Augustin, Andreas Rosenwald, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet Ambarkhane, Gilles Salles
Publikováno v:
Haematologica, Vol 999, Iss 1 (2021)
Not available.
Externí odkaz:
https://doaj.org/article/87ddd8a6674b4a1a85c63967777aba9a
Autor:
Mark Winderlich, Sumeet Ambarkhane, Wolfram Brugger, Maren Dirnberger-Hertweck, Wing Hang Leung, Elias Jabbour, Rebecca B. Klisovic
Publikováno v:
Cancer. 127:4190-4197
BACKGROUND B-precursor cell acute lymphoblastic leukemia (B-ALL) in adults is an aggressive and challenging condition, and patients with relapsed/refractory (R/R) disease after allogeneic stem cell transplantation (SCT), or noncandidates for SCT, hav
Autor:
Kami J. Maddocks, Johannes Duell, Eva González-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven de Vos, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Marc André, Martin Dreyling, Tobias F Menne, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet Ambarkhane, Gilles Salles
Publikováno v:
Blood. 136:19-21
Introduction Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) have a poor prognosis. Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody t
Autor:
Pau Abrisqueta, Martin Dreyling, Johannes Duell, Marc André, Eva González-Barca, Aleš Obr, Gilles Salles, Nagesh Kalakonda, Tobias Menne, Olivier Tournilhac, Gianluca Gaidano, Anna Marina Liberati, Sven de Vos, Sumeet Ambarkhane, Wojciech Jurczak, Johannes Weirather, Maren Dirnberger-Hertweck, Kami J. Maddocks, Zsolt Nagy, Andreas Rosenwald, Marinela Augustin
Publikováno v:
Haematologica, Vol. 106, no. 9, p. 2417-2426 (2021)
Haematologica
Haematologica, Ferrata Storti Foundation, 2021, 106 (9), pp.2417-2426. ⟨10.3324/haematol.2020.275958⟩
Scientia
Publons
Dipòsit Digital de la UB
Universidad de Barcelona
Haematologica
Haematologica, Ferrata Storti Foundation, 2021, 106 (9), pp.2417-2426. ⟨10.3324/haematol.2020.275958⟩
Scientia
Publons
Dipòsit Digital de la UB
Universidad de Barcelona
Tafasitamab; B-cell lymphoma Tafasitamab; Linfoma de células B Tafasitamab; Limfoma de cèl·lules B Tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the immunomodulatory drug lenalidomide was clinically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81c3367494a28c41564cb0858be61c03
http://hdl.handle.net/2445/180067
http://hdl.handle.net/2445/180067
Autor:
Maren Dirnberger-Hertweck, Peter Neumeister, Peter Kelemen, Philipp B. Staber, Wojciech Jurczak, Jennifer A. Woyach, Marco Montillo, Wolfram Brugger, Talha Munir, Johannes Schetelig, Richard Greil, Frank Striebel, Johannes Weirather, Jan Moritz Middeke, Stephan Stilgenbauer, Clemens-Martin Wendtner, Vladan Vucinic
Patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) whose treatment failed with a Bruton's tyrosine kinase inhibitor have poor outcomes. We investigated tafasitamab plus idelalisib (cohort A) or venetoclax (cohort B) in this pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::489d1616b2f22d2ce376f07b65732ef7
https://ruj.uj.edu.pl/xmlui/handle/item/290233
https://ruj.uj.edu.pl/xmlui/handle/item/290233
Autor:
Nagesh Kalakonda, Günter Fingerle-Rowson, Marc André, Eva González Barca, Sumeet Ambarkhane, Zsolt Nagy, Aleš Obr, Gilles Salles, Olivier Tournilhac, Kami J. Maddocks, Gianluca Gaidano, Johannes Duell, Maren Dirnberger-Hertweck, Anna Marina Liberati, Johannes Weirather, Wojciech Jurczak, Martin Dreyling
Publikováno v:
The Lancet Oncology
The Lancet Oncology, 2020, 21 (7), pp.978-988. ⟨10.1016/S1470-2045(20)30225-4⟩
The Lancet. Oncology, Vol. 21, no. 7, p. 978-988 (2020)
Lancet Oncology
Lancet Oncology, Elsevier, 2020, 21 (7), pp.978-988. ⟨10.1016/S1470-2045(20)30225-4⟩
The Lancet Oncology, 2020, 21 (7), pp.978-988. ⟨10.1016/S1470-2045(20)30225-4⟩
The Lancet. Oncology, Vol. 21, no. 7, p. 978-988 (2020)
Lancet Oncology
Lancet Oncology, Elsevier, 2020, 21 (7), pp.978-988. ⟨10.1016/S1470-2045(20)30225-4⟩
Summary Background Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatment options. Tafasitamab (MOR208) is an Fc-enhanced, humanised, anti-CD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e924b5648e9c49e092c3b777842021f
https://hal.archives-ouvertes.fr/hal-02935846
https://hal.archives-ouvertes.fr/hal-02935846
Autor:
Eva González-Barca, Marc André, Pau Abrisqueta, Johannes Weirather, Aleš Obr, Gianluca Gaidano, Kami J. Maddocks, Gilles Salles, Johannes Düll, Wojciech Jurczak, Sumeet Ambarkhane, Tobias Menne, Anna Marina Liberati, Martin Dreyling, Maren Dirnberger-Hertweck
Publikováno v:
Journal of Clinical Oncology. 39:7513-7513
7513 Background: L-MIND (NCT02399085) is an ongoing, open-label, Phase II study of tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, plus LEN in ASCT-ineligible patients (pts) with R/R DLBCL. Primary analyses and 2-year
Autor:
Johannes Duell, Martin Dreyling, Johannes Weirather, Kami J. Maddocks, Eva González-Barca, Marc André, Gianluca Gaidano, Anna Marina Liberati, Aleš Obr, Nagesh Kalakonda, Zsolt Nagy, Gilles Salles, Olivier Tournilhac, Tobias Menne, Maren Dirnberger-Hertweck, Wojciech Jurczak, Sven de Vos, Pau Abrisqueta, Sumeet Ambarkhane, Marinela Augustin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S267-S268
Context: Tafasitamab, a humanized anti-CD19 antibody, has demonstrated encouraging activity with durable responses with lenalidomide (LEN) in autologous stem cell transplant (ASCT)-ineligible patients with relapsed/refractory (R/R) diffuse large B-ce
Autor:
Gianluca Gaidano, Wojciech Jurczak, Kristie A. Blum, Mariano Provencio, Johannes Weirather, Sascha Tillmanns, Sumeet Ambarkhane, Christian Buske, Kami J. Maddocks, Zsolt Nagy, Pier Luigi Zinzani, Maren Dirnberger-Hertweck, Georg Hess, Wolfram Brugger, Tadeusz Robak
Publikováno v:
Blood. 134:4078-4078
Background: CD19 is broadly and homogeneously expressed across different B-cell malignancies and represents an attractive target antigen in patients with B-cell non-Hodgkin's lymphoma (NHL). Tafasitamab (MOR208) is an Fc-enhanced, humanized, anti-CD1
Autor:
Aleš Obr, Maren Dirnberger-Hertweck, Zsolt Nagy, Gilles Salles, Wojciech Jurczak, Sven de Vos, Pau Abrisqueta, Kami J. Maddocks, Sumeet Ambarkhane, Tobias Menne, Marc André, Eva González-Barca, Anna Marina Liberati, Johannes Weirather, Martin Dreyling, Johannes Duell, Gianluca Gaidano
Publikováno v:
Blood. 134:1582-1582
Introduction Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) have a poor prognosis. Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody t